Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    19064971 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma
Condition: Leukemia-Lymphoma, Adult T-Cell
Interventions: Drug: Bortezomib;   Drug: Etoposide;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: Prednisone;   Drug: Cyclophosphamide;   Drug: Raltegravir
2 Recruiting Ruxolitinib for Adult T-Cell Leukemia
Conditions: T Cell Leukemia, Adult;   Leukemia, Adult T-Cell;   T Cell Leukemia, HTLV I Associated
Intervention: Drug: Ruxolitinib

Indicates status has not been verified in more than two years